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Objectives . Silent myocardial ischemia is common in patients
with diabetes . This study was designed to assess the role of
subclinical autonomic impairment in diabetic patients with silent
ischemia.
Background. Studies have suggested that silent ischemin is
more common in diabetic pathmis with microvaqcular complica-
tions, but this has not been a consistent finding.
Methods. Twenty-two diabetic and 30 nondlabelic patients with
proved coronary artery disease and a history of angina and
Ischemia on treadmill stress testing underwent clinical tests of
autonomic function and measurement of 24-h heart rate variabil-
ity . Diabetic patients with a history of microvascular complica.
tions were excluded .
Results. Although all 52 patients manifested ischemia during
treadmill testing, only 36 patients experienced angina (angina
group), whereas 16 did not (silent ischemis group) . Diabetic and
nondiabetic patients were similar in age (59 ± 1 vs . 61 ± 2 years,
Diabetic patients are particularly prone to silent myocardial
infarction (1,2), which has been attributed to autonomic
neuropathy affecting the sensory innervation of the heart
(3,4) . Whether silent ischemia is also more prevalent in
diabetic patients is uncertain . Some investigators have re-
ported an increased prevalence (5,6), but Callaham et al . (7)
found that silent ischemia was no more common in diabetic
patients undergoing treadmill stress testing . The role of
autonomic neuropathy is also controversial . Thus, although
some investigators have reported a relation between silent
ischemia and neuropathy in patients with diabetes (8), others
have been unable to confirm this (9) .
We (10) have previously shown that diabetic patients who
experience angina during treadmill stress testing take almost
twice as long to develop symptoms after the onset of ST
segment depression as do nondiabetic control subjects . In
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p = 0.56) and extent of coronary artery disease . However, clinical
tests showed reduced parasympathetic function in the diabetic
patients (Valsaiva ratio 1.38 ± 0.07 vs . 1 .60 ± 0.06, p = 0.007) .
Patients in the silent ischemia group were more often diabetic
(33% vs . 63%, p = 0.05) and had prolonged time to isehemia on
treadmill testing (200 ± 20 vs . 271 ± 20 s, p = 0 .03) : In aildition,
autonomic function was impaired in the silent group (supine/
standing heart rate ratio 1 .15 ± 0 .02 vs. 1 .05 ± 0.02, p = 0 .002) .
Subgroup analysis showed that abnormalities of autonomic func-
lion were confined to the diabetic patients in the silent group.
Conclusions . Despite the absence of overt microvascular com-
plications, diabetic patients with silent exertional ischemia have
evidence of significant autonomic impairment compared with
findings in symptomatic patients . This difference is not seen in
nondiabetic patients and indicates that subclinical neuropathy is
an important cause of silent isehemia in patients with diabetes .
(J Am Coll Cardiol 1993,22 .-1433-7)
the present study, attention was directed toward patients
with silent exertional ischemia during treadmill testing who
were compared with symptomatic control subjects. The
purpose of the study was to clarify the role of autonomic
neuropathy in the pathophysiology of silent ischemia using
clinical tests of autonomic function and measures of heart
rate variability, which are particularly sensitive to subclini-
cal neuropathic changes in diabetic patients (11-13) .
Methods
Ethical approval . The study was approved by the
Newham Health District Ethical Committee, and written
informed consent was given by all patients .
Patients. Patients were recruited consecutively from
those undergoing exercise treadmill testing for the assess-
ment of angina . Any patient who developed ?0
.I mV of
planar or downsloping ST segment depression on exercise
treadmill testing was eligible . Patients with diabetes were
excluded if there was a history of impotence or postural
hypotension or evidence of other microvascular complica-
tions (retinopathy or microalbuminuria). Patients with symp-
toms or clinical signs of peripheral neuropathy or any other
neurologic disease or a history of alcohol abuse were also
excluded
. Normal renal and liver function and hemoglobin
07351057193156 .00
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Table 1 .
Clinical Characteristics, Exercise Variables and Autonomic Function in Nondiabetic and
Diabetic Patients
levels were confirmed in all cases . The study group com-
prised 52 patients who fulfilled these criteria . There were
41 men and I I women, with a mean age of 60 ± I years
(range 37 to 77)
Study design . Antianginal medication was withdrawn
S days before the study, but short-acting nitrates were
disallowed only on the day of the study. No medication was
taken on the morning of the study. Patients underwent an
exercise treadmill test, autonomic function tests and assess-
ment of heart rate variability .
Exorcise treadmill test. A symptom-limited treadmill test
was performed according to the Bruce protocol. A 12-
channel electrocardiogram (ECG) was monitored continu-
ously, and blood pressure was recorded at baseline, at the
end of each exercise stage, at the onset of ischemia (defined
as 0.1 mV of planar or downsloping ST segment depression)
and at peak exercise. Exercise was stopped when the patient
indicated that the limit of exercise tolerance was reached, or
sooner if any of the following occurred : a decrease in
systolic blood pressure >10 mm Hg, significant ventricular
arrhythmias or >0.5-mV ST segment depression. On the
basis of the test, patients were classified into the angina
group (those who developed angina during treadmill testing)
or the silent ischemia group (those who did not develop
angina).
Aubmamic function tests. Five standard tests were per-
formed (14) that are known to be repeatable (15): Valsalva
ratio, supineistanding heart rate ratio, heart rate variation
during deep breathing, systolic blood pressure response to
Values presented are mean value t SEM or number
. pNNSO = proportion of adjacent RR intervals >50 ms
different ; rMSSD = root mean square .'difference of successive RR intervals, SDANN = standard deviation of
5-min mean RR intervals.
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standing from the supine position and increase in diastolic
blood pressure with sustained handgrip .
Heart rate variability . Patients underwent 24-h ambula-
tory ECG (Halter) monitoring for measurement of heart rate
variability, which has previously been shown to be repeat-
able (16,17). Holter monitoring was similarly performed
while the patient was taking no antianginal therapy . Record-
ings were made using a Marquette Series 8000 recorder, and
spectral and nonspectral measures of heart rate variability
were made using Marquette software .
Coronary angiography and ventriculography . All patients
underwent routine coronary angiography to confirm the
presence of coronary artery disease, which was quantified
by counting the number of main vessels with >75% diameter
stenosis . Left ventricular function was calculated from stan-
dard contrast ventriculography using the area method .
Statistical analysis. All averaged results are expressed as
mean value ± SEM . The angina and silent ischemia groups
and the diabetic and nondiabetic patients were compared
using the unpaired t test for normally distributed variables
and by the Mann-Whitney U test for other variables (left
ventricular ejection fraction, blood pressure measure during
treadmill testing, exercise time on treadmill, all measures of
heart rate variability, Valsalva ratio and
supine/standing
blood pressure) . The distribution of multivessel coronary
artery disease and diabetic patients were compared using the
chi-square test. Two-sided p values were considered signif-
icant at the 5% level .
Nondiabetic
Patients
(n = 30)
Diabetic
Patients
(n = 22)
p Value
Age (yr)
61±2 59 ± 1
0.56
Male patients
23
18 0 .92
Single-/multivessel dis;ase
8122 8/14 0.66
Left ventricular ejection fraction ( 17o)
57 ± 1
56±-2 0.74
Time to ischemia (s)
207 ± 20
244 ± 23 0.24
Exercise duration (s)
383 ± 33 355 ± 22 0.97
Autonomic function
Clinical tests
Valsalva ratio
1 .60 ± 0.06
1 .38 ± 0.07 0,007
Supinelstanding heart rate ratio
1 .15 ± 0.02 1 .08 ± 0.02 0.02
Heart rate variation, deep breathing (beatsimin)
17,4±1 .5 12.1±1.5 0.02
Decrease in systolic pressure, QmWanlq (mm Hg)
8±2 8±2 0.98
Increase in diastolic pressure, handgrip (mm Hg)
25 ± 1 21 ± 2 0.15
Heart rate variability
High frequency (0.15-0 .40 Hz) peak (ms)
10 .0± 1 .0 13.010.8 0,45
Low frequency (0.04-0.15 Hz) peak (ms)
23 .9 ± 2 .1 21 .8 ± 1 .7 0,85
SDANN (ms) 130 ± 7 106 ± 5 0,06
rMSSD NO 26.4±3.5
24.8±1.8
0 .56
pNN50 (%)
7.0±2.0 5.4±1.0 0.63
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Table 2 . Clinical Characteristics and Exercis- Variables in the
Angina and Silent Ischemia Groups
Values presented are mean value ± SEM or number (`l) .
ReSKS
Diabetic versus nondiabetic patients (Table 1) . Of the 52
patients included in the study, 22 (42%) were diabetic. There
were no differences between the diabetic and nondiabetic
patients with regard to age, left ventricular function and
severity of coronary artery disease . However, clinical tests
showed reduced parasympathetic function in the diabetic
patients, and measures of heart rate variability tended to be
lower .
Stress testing (Table 2) . Although all patients developed
ischemia, only 36 (69%) experienced angina (angina group) .
In the remainder, exertional ischemia was silent (silent
ischemia gtitip) . The silent ischemia group contained rela-
tively more diabetic patients than did the angina group
(33% vs. 63%, p = 0 .05), but there were no differences
between groups with regard to age, left ventricular function
and severity of coronary disease . However, time to ischemia
and exercise duration were all significantly greater in the
angina group .
Autonomic function testing (Tables 3 and 4) . The silent
ischemia group showed significant parasympathetic impair-
Table 3
. Autonomic Function in the Angina and Silent Groups
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ment compared with findings in the angina group, as re-
flected by reductions in the Valsalva and supine/sLarlding
heart rate ratios . Parasympathetic impairment in the silent
ischemia group was associated with a consistent trend to-
ward reduced heart rate variability . Subgroup analysis
(Table 4) showed that these differences in autonomic func-
tion between groups were confined to the diabetic patients .
Discussion
Mechanisms of silent myocardial ischemia . There are two
main theories to account for silent ischemia . The first in the
mass effect, which proposes that a critical amount of myo-
cardium is rendered ischemic before symptoms develop so
that patients with less extensive coronary disease are less
likely to experience pain . The second is abnormalities in the
perception of ischemia, perhaps caused by impairment of
nerve conduction in pain pathways (18) .
Role of severity of ischemia . In this study of exerfiorial
myocardial ischemia, we examined diabetic and nondiabetic
patients, all of whom had stable angina . To study a homo-
geneous group of diabetic patients, we were careful to
exclude those with microvascular complications. We found
an excess of diabetic patients among the group that experi-
enced no angina during treadmill stress testing . However,
the severity of coronary artery disease was no less severe in
diabetic than in nondiabetic patients or in the silent ischemia
compared with the angina group. Indeed, in the diabetic
patients, ST segment depression tended to occur earlier
during treadmill stress testing, suggesting that ischemia in
this group may be more severe than in nondiabetic patients .
It is unlikely therefore that any propensity to silent ischemia
in the patients with diabetes was due to a smaller mass of
ischemic myocardium .
Role of impaired perception . If silent ischemia in diabetes
cannot be explained by the theory of ischemic mass, percep-
tual abnormalities rrovide a likely alternative . Patients with
diabetes frequeialy have impaired nerve conduction due to
Values presented are mean value ± SEM
. Abbreviations as in Table I
.
Autonomic Function
Angina
Group
(n = 36)
Silent Ischemia
Group
(n = 16)
p Value
Clinical tests
Valsalva ratio
1 .56 ± 0.05
1 .40 ± 0
.09
0 .08
Supine/standing heart rate ratio
1 .15 ± 0 .02
1 .05 ± 0 .02 0002
Heart rate variation, deep breathing (beats/min)
15 .9± 1 .2
13.6±2.4 0.30
Decrease in systolic pressure, supine/standing (mm Hg)
8.6± 1 .3
7.6±2.6
0.70
Increase in diastolic pressure, handgrip (mm Hg)
24
.7 ± 1
.3
21 .9 ± 1 .8
0.32
Heart rate variability
High frequency (0
.15-0 .40 Hz) peak (ms)
10.4±0 .8
9.4^_:1 .2
OA3
Low frequency (0
.04-0 .15 Hz) peak (ms)
24.3±1
.8
19.9±17 0.23
SDANN (ms)
123 ± 6
111 ± 8
0.23
rMSSD (ms)
27.2±2
.7 22.2±2
.6 0.12
pNN50 (%)
7.0-1 .5
4.8±1 .9
0 .10
Angina
Group
(a = 36)
Silent
IschCmia
Group
(n = 16)
p
Value
Age (y) 60 ± 2 60 ± 2 0.90
Diabetic patients 12 (33)
10(63) 0.05
Single4multivessel disease 10/26 6/10 Ull
Left ventricular ejection
fraction (%)
57 ± 1 56 ± 2 0.59
Time to ischemia (s) 200 ± 20 271 ± 20 0.03
Exercise duration (s) 329 ± 22 466 m 38
0
.003
Sum of ST segment
depression (mV)
0 .140 ± 0 .08 0.90 ± 0.23 0.69
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Table 4 .
Autonomic Function in the Angina and Silent Groups of Diabetic and Nondiabetic Patients
Values presented are mean value ± SEM. Abbreviations as in Table I
.
microvascular disease, and postmortem studies have asso-
ciated silent myocardial infarction with neuropathic changes
in intracardiac sympathetic and parasympathetic afferent
fibers (4) . However, clinical evidence for an association
between silent myocardial ischemia and neuropathy has
been conflicting . Langer et al. (8) studied 58 patients with
diabetes and no clinical evidence of cardiac disease and
found that myocardial perfusion defects on thallium scintig-
raphy were more common in those with impaired autonomic
function. In contrast, Nesto et al . (5), although confirming a
high prevalence of silent exertional ischemia in diabetic
patients with abnormal thallium scintigrams, could find no
difference in microvascular complications between the silent
ischemia and symptomatic subgroups .
Diabetic versus nondlabetic patients . In the present study,
evaluation of autonomic function utilized not only bedside
techniques but also measures of heart rate variability, which
are particularly sensitive to early neuropathy in diabetes
(12). We found significant abnormalities of autonomic func-
tion in the patients with silent ischemia, as reflected by
reductions in the Valsalva and supinelstanding heart rate
ratios. In addition, there was a consistent trend toward
reduced heart rate variability on Hotter monitoring . How-
ever, the data in Table 4 clearly show that the autonomic
abnormality in the patients with silent ischemia was confined
to the diabetic subgroup
. In the latter, the parasympathetic
defect on standard bedside testing was associated with
significant reductions in parasympathetic indexes of heart
rate variability (low frequency spectral peak, root mean
square of difference of successive RR intervals and the
proportion of adjacent RR intervals >50 ms different) com-
pared with findings in the symptomatic patients . In contrast,
in the nondiabetic subgroup, autonomic function was gener-
ally better preserved and showed no tendency toward im-
pairment in those who experienced no symptoms .
JACC Vol
. 22, No
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Conclusions . This study showed that despite the absence
of overt microvascular complications, diabetic patients with
silent exertional ischemia have evidence of significant auto-
nomic impairment compared with findings in symptomatic
patients . This difference is not seen in nondiabetic patients
and indicates that subclinical neuropathy is an important
cause of silent ischemia in patients with diabetes .
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